Hexon hypervariable region-modified adenovirus 5 vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors.

Teigler JE, Penaloza-MacMaster P, Obeng R, Provine NM, Larocca RA, Borducchi EN, Barouch DH. Hexon hypervariable region-modified adenovirus 5 vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors. Clin. Vaccine Immunol. 2014; 21:1137-1144.

Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies.

Dugast AS, Chan Y, Hoffner M, Licht A, Nkolola J, Li H, Streeck H, Suscovich TJ, Ghebremichael M, Ackerman ME, Barouch DH, Alter G. Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. PLoS One 2014; 9:e97229.

Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity.

Teigler JE, Kagan JC, Barouch DH. Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity. J. Virol. 2014; 88:10354-10363.

Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.

Provine NM, Larocca RA, Penaloza-MacMaster P, Borducchi EN, McNally A, Parenteau LR, Kaufman DR, Barouch DH. Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses. J. Immunol. 2014; 192:5214-5225.

Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys

Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, Parenteau L, Cabral C, Shields J, Blackmore S, Smith JY, Brinkman AL, Peter LE, Mathew SI, Smith KM, Borducchi EN, Rosenbloom DIS, Lewis MG, Hattersley J, Li B, Hesselgesser J, Geleziunas R, Robb ML, Kim JH, Michael NL, Barouch DH. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 2014; 512:74-77.

The canarypox vector ALVAC induces distinct cytokine responses compared to the vaccinia-based vectors MVA and NYVAC in rhesus monkeys.

Teigler JE, Phogat S, Franchini G, Hirsch VM, Michael NL, Barouch DH. The canarypox vector ALVAC induces distinct cytokine responses compared to the vaccinia-based vectors MVA and NYVAC in rhesus monkeys. J. Virol. 2014; 88:1809-1814.

The immune space: a concept and template for rationalizing vaccine development.

Manrique A, Adams E, Barouch DH, Fast P, Graham BS, Kim JH, Kublin JG, McCluskey M, Pantaleo G, Robinson HL, Russell N, Snow W, Johnston MI. The immune space: a concept and template for rationalizing vaccine development. AIDS Res. Hum. Retroviruses 2014; 30:1017-1022.

A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 Vaccine: Evidence for transient T cell responses in peripheral blood and robust sustained responses in the lungs.

Hokey DA, Wachholder R, Darrah PA, Bolton DL, Barouch DH, Hill K, Dheenadhayalan V, Schwander S, Godin CS, Douoguih M, Pau MG, Seder RA, Roederer M, Sadoff JC, Sizemore D. A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 Vaccine: Evidence for transient T cell responses in peripheral blood and robust sustained responses in the lungs. Hum. Vaccin. Immunother. 2014; 10:2199-2210.

Adenovirus serotype 26 and 35 vectors induce simian immunodeficiency virus-specific T lymphocyte responses in foreskin in rhesus monkeys.

Balandya E, Miller AD, Beck M, Liu J, Li H, Borducchi E, Smith K, Cabral C, Stanley K, Maxfield LF, Barouch DH. Adenovirus serotype 26 and 35 vectors induce simian immunodeficiency virus-specific T lymphocyte responses in foreskin in rhesus monkeys. J. Virol. 2014; 88:3756-3765.

Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens.

Penaloza-MacMaster P, Teigler JE, Obeng RC, Kang ZH, Provine NM, Parenteau L, Blackmore S, Ra J, Borducchi EN, Barouch DH. Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens. J. Virol. 2014; 88:6243-6254.